---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-26-000002"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:10:10.270934+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Curis raises up to $80.8M in PIPE financing; extends cash runway into 2027

## Summary
- Initial gross proceeds of ~$20.2M from sale of Series B Preferred Stock and warrants; potential total up to ~$80.8M if warrants exercised.
- Warrants to purchase up to 26.9M shares each (Series A, B, C) at $0.75 exercise price; exercisable after stockholder approval.
- Proceeds expected to extend cash runway into 2027; focus on Phase 2 combo study of emavusertib in CLL and PCNSL.
- Purchasers include CEO, CFO, CMO, CDO and a board member.
- PIPE proceeds believed to sustain stockholders’ equity above Nasdaq $2.5M minimum; delisting hearing pending.

## SEC filing metadata
- accession: 0001108205-26-000002
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000002/0001108205-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000002/cris-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-26-000002
- JSON: https://secwatch.observer/filing/0001108205-26-000002.json
- Plain text: https://secwatch.observer/filing/0001108205-26-000002.txt

## Source-grounded claims
- claim_id: 4ea92c843930d63a886054fddbd381dfcc26f579
  claim: CURIS INC: Filed Certificate of Designations for Series B Convertible Non-Redeemable Preferred Stock, designating 20,195 shares with specific rights, preferences, and privileges (effective 2026-01-07).
  evidence_excerpt: Pursuant to the terms of the Purchase Agreement, on January 7, 2026 (the “Filing Date”), the Company filed the Certificate of Designations with the Secretary of State of the State of Delaware designating 20,195 shares of its authorized and unissued preferred stock as Series B Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000002/0001108205-26-000002-index.htm
- claim_id: 2d83bf11b4149e26728f00ad0bd47a0c5290d1f4
  claim: CURIS INC entered into Securities Purchase Agreement with the purchasers named therein valued at up to approximately $80.8 million (effective 2026-01-07).
  evidence_excerpt: On January 7, 2026, Curis, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell an aggregate of (i) 20,195 shares of its Series B convertible non-redeemable preferred stock, par value $0.01 per share (the “Series B Preferred Stock”), (ii) Series A warrants
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820526000002/0001108205-26-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.